Cresset Asset Management LLC raised its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 3.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 192,129 shares of the company's stock after acquiring an additional 5,960 shares during the quarter. Cresset Asset Management LLC owned approximately 0.16% of Henry Schein worth $13,159,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in the business. Barclays PLC lifted its holdings in Henry Schein by 0.7% in the 4th quarter. Barclays PLC now owns 288,523 shares of the company's stock worth $19,964,000 after purchasing an additional 2,048 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Henry Schein during the fourth quarter valued at approximately $296,000. Guggenheim Capital LLC lifted its holdings in shares of Henry Schein by 2.5% in the fourth quarter. Guggenheim Capital LLC now owns 6,428 shares of the company's stock worth $445,000 after buying an additional 159 shares in the last quarter. Forum Financial Management LP purchased a new position in shares of Henry Schein in the fourth quarter worth $221,000. Finally, Fiduciary Management Inc. WI boosted its position in shares of Henry Schein by 7.2% during the fourth quarter. Fiduciary Management Inc. WI now owns 2,488,335 shares of the company's stock worth $172,193,000 after acquiring an additional 167,990 shares during the last quarter. Institutional investors own 96.62% of the company's stock.
Analyst Ratings Changes
HSIC has been the topic of several research reports. UBS Group reduced their target price on Henry Schein from $75.00 to $70.00 and set a "neutral" rating on the stock in a report on Wednesday, August 6th. Stifel Nicolaus reaffirmed a "hold" rating and set a $75.00 price target (down from $80.00) on shares of Henry Schein in a research note on Friday, July 25th. Wells Fargo & Company lowered their target price on shares of Henry Schein from $80.00 to $75.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Leerink Partners set a $75.00 price objective on Henry Schein in a report on Monday, July 14th. Finally, Baird R W downgraded shares of Henry Schein from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 14th. Four research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $75.58.
Check Out Our Latest Analysis on HSIC
Henry Schein Stock Up 0.5%
Shares of HSIC stock traded up $0.33 during trading hours on Wednesday, reaching $68.64. 2,059,320 shares of the company's stock were exchanged, compared to its average volume of 1,773,902. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $82.49. The stock's 50 day moving average is $70.67 and its 200-day moving average is $70.61. The company has a current ratio of 1.41, a quick ratio of 0.78 and a debt-to-equity ratio of 0.51. The company has a market cap of $8.32 billion, a price-to-earnings ratio of 22.14, a P/E/G ratio of 2.22 and a beta of 0.81.
Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.10 earnings per share for the quarter, missing the consensus estimate of $1.19 by ($0.09). Henry Schein had a return on equity of 14.36% and a net margin of 3.05%.The business had revenue of $3.24 billion for the quarter, compared to analysts' expectations of $3.22 billion. During the same quarter last year, the firm earned $1.23 earnings per share. The firm's quarterly revenue was up 3.3% compared to the same quarter last year. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. Analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.
Henry Schein Profile
(
Free Report)
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Articles

Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.